Oculis Holding AG (OCS) Amortization of Deferred Charges (2022 - 2024)

Oculis Holding AG's (OCS) quarterly Amortization of Deferred Charges came in at $50410.0 in Q1 2024, up 66.52% year-on-year from $30272.6 in Q2 2023, and down 0.63% quarter-over-quarter from $50731.0 in Q4 2023.

Oculis Holding AG (OCS) Amortization of Deferred Charges (2022 - 2024) Analysis & Trends

Oculis Holding AG's Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $50410.0 for Q1 2024.

  • On a quarterly basis, Amortization of Deferred Charges rose 66.52% year-over-year to $50410.0 in Q1 2024; TTM through Mar 2024 was $201003.6, a N/A change from a year earlier, with the FY2024 full-year figure at $310319.5, up 72.04% from the prior year.
  • Amortization of Deferred Charges fell to $50410.0 in Q1 2024 per OCS's latest filing, from $50731.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $50731.0 in Q4 2023 and bottomed at $30272.6 in Q1 2023.
  • The 3-year median for Amortization of Deferred Charges is $49814.7 (2023), against an average of $45629.0.
  • Across the five-year window, Amortization of Deferred Charges rose 11.07% in 2023 and surged 66.52% in 2024, its largest moves.
  • Year by year, Amortization of Deferred Charges stood at $45673.0 in 2022, then climbed by 11.07% to $50731.0 in 2023, then slipped by 0.63% to $50410.0 in 2024.
  • Per Business Quant, the three latest OCS Amortization of Deferred Charges figures stand at $50410.0 (Q1 2024), $50731.0 (Q4 2023), and $49814.7 (Q3 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2024 50,410.02
Mar 31, 2024 50,410.02
Dec 31, 2023 50,730.95
Dec 31, 2023 50,730.95
Sep 30, 2023 49,814.71
Sep 30, 2023 49,814.71
Jun 30, 2023 50,047.90
Jun 30, 2023 50,047.90
Mar 31, 2023 30,272.55
Mar 31, 2023 30,272.55
Dec 31, 2022 45,672.96
Dec 31, 2022 45,672.96
Sep 30, 2022 42,453.72
Sep 30, 2022 42,453.72